Stroke & Cerebrovascular Disease

Acute stroke care has been redefined by tenecteplase displacing alteplase as the preferred thrombolytic, late-window thrombectomy out to 24 hours guided by perfusion imaging (DAWN, DEFUSE-3), and increasingly the treatment of medium and distal vessel occlusions. GCNN 2027 will examine direct-to-angio-suite workflows, mobile stroke units, and the expanding evidence for thrombectomy in large core infarcts (SELECT2, ANGEL-ASPECT). The track will also cover secondary prevention with factor XI inhibitors, PFO closure post-RoPE, and the persistent gap in primary prevention for cerebral small vessel disease.